HKSE · 9969.HK
InnoCare Pharma Limited
HK$11.64-HK$0.03 (-0.26%)
InnoCare Pharma Limited’s quoted price sits in the lower half of its reported 52-week range, 28.4% below the high.
Loading market information…
HKSE · 2105.HK · HKD
Stock price, earnings
Quote as of Oct 30, 2026, 05:10 AM UTC. Cached market data; not a live quote.
One-year closing-price history · HKD. Historical prices are not a forecast.
Laekna, Inc.’s quoted price sits in the lower half of its reported 52-week range, 70.17% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Laekna, Inc.’s next earnings report is currently expected on Mar 30, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Laekna, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Laekna, Inc., an investing holding company, engages in the discovering, development, and commercialization of therapies for patients with cancer, metabolic diseases, and liver fibrosis worldwide. The company offers LAE002, an adenosine triphosphate competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, and breast cancer; LAE001, an androgen synthesis inhibitor that inhibits CYP17A1 and CYP11B2 to treat prostate cancer; LAE005, a ligand-blocking humanized anti-PD-L1 IgG4 antibody for the treatment of triple-negative breast cancer; and LAE102, a monoclonal antibody against ActRIIA to treat obesity. It also develops LAE111, LAE112, LAE113, LAE119, and LAE120 for the treatment of cancer; LAE118, a PI3Ka mutant-selective inhibitor; LAE103 for Sarcopenia; LAE123 to treat muscle and other disease indications; LAE104 and LAE105 for the treatment of liver fibrosis; and LAE106 to treat fibrosis. The company has a collaboration with Eli Lilly and Company for the development of LAE102. Laekna, Inc. was incorporated in 2016 and is headquartered in Yuyao, China.
Latest available per-share figures in HKD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:27 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
KEEP COMPARING
HK$11.64-HK$0.03 (-0.26%)
InnoCare Pharma Limited’s quoted price sits in the lower half of its reported 52-week range, 28.4% below the high.
HK$28.30+HK$0.08 (+0.28%)
Ascentage Pharma Group International’s quoted price sits in the lower half of its reported 52-week range, 59.19% below the high.
HK$5.14+HK$0.40 (+8.45%)
CStone Pharmaceuticals’s quoted price sits in the lower half of its reported 52-week range, 50.67% below the high.
HK$6.35-HK$0.14 (-2.16%)
Alphamab Oncology’s quoted price sits in the lower half of its reported 52-week range, 47.95% below the high.
HK$3.23+HK$0.17 (+5.38%)
Lepu Biopharma Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 53.05% below the high.
HK$6.37+HK$0.03 (+0.47%)
Abbisko Cayman Limited’s quoted price sits in the lower half of its reported 52-week range, 57.82% below the high.
HK$4.73+HK$0.10 (+2.16%)
Jacobio Pharmaceuticals Group Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 49.09% below the high.
HK$8.92+HK$0.27 (+3.06%)
TransThera Sciences (Nanjing). Inc.’s quoted price sits in the lower half of its reported 52-week range, 96.37% below the high.
